These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30747296)

  • 1. Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis.
    Sternlicht H; Bakris GL
    Curr Hypertens Rep; 2019 Feb; 21(2):12. PubMed ID: 30747296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of SGLT2i on 24-hour ambulatory blood pressure in patients with type 2 diabetes complicating hypertension: a meta-analysis].
    Tian L; Wang QY; Sun RM; Qi MM; Li YX; Gao X; Zhang LQ; Ma X; Shi H; Yu J; Bai F
    Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Oct; 49(10):1000-1011. PubMed ID: 34674438
    [No Abstract]   [Full Text] [Related]  

  • 3. Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease.
    Kario K; Ferdinand KC; O'Keefe JH
    Prog Cardiovasc Dis; 2020; 63(3):249-262. PubMed ID: 32275926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension.
    Musini VM; Nazer M; Bassett K; Wright JM
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD003824. PubMed ID: 24869750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials.
    Liu J; Pong A; Gallo S; Darekar A; Terra SG
    Cardiovasc Diabetol; 2019 May; 18(1):59. PubMed ID: 31064361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose co-transporter-2 inhibitors: peculiar "hybrid" diuretics that protect from target organ damage and cardiovascular events.
    Sarzani R; Giulietti F; Di Pentima C; Spannella F
    Nutr Metab Cardiovasc Dis; 2020 Sep; 30(10):1622-1632. PubMed ID: 32631704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure.
    Scheen AJ
    Curr Cardiol Rep; 2019 Jun; 21(8):70. PubMed ID: 31227915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.
    Pfeifer M; Townsend RR; Davies MJ; Vijapurkar U; Ren J
    Cardiovasc Diabetol; 2017 Feb; 16(1):29. PubMed ID: 28241822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease.
    Górriz JL; Navarro-González JF; Ortiz A; Vergara A; Nuñez J; Jacobs-Cachá C; Martínez-Castelao A; Soler MJ
    Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i13-i23. PubMed ID: 32003834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes.
    Yaribeygi H; Atkin SL; Sahebkar A
    Diabetes Metab Syndr; 2019; 13(2):1679-1683. PubMed ID: 31336541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the Sodium-Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2.
    McCullough PA; Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Kluger SL; Rangaswami J
    Rev Cardiovasc Med; 2018 Jun; 19(2):51-63. PubMed ID: 31032603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management.
    Katsiki N; Mikhailidis DP; Theodorakis MJ
    Curr Pharm Des; 2017; 23(10):1522-1532. PubMed ID: 28088910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients.
    Guasti L; Gaudio G; Lupi A; D'Avino M; Sala C; Mugellini A; Vulpis V; Felis S; Sarzani R; Vanasia M; Maffioli P; Derosa G
    Drug Des Devel Ther; 2017; 11():2293-2300. PubMed ID: 28831241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction.
    Heerspink HJL; Kohan DE; de Zeeuw D
    Kidney Int; 2021 Feb; 99(2):346-349. PubMed ID: 33144213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Spectrum and Mechanism of Acute Kidney Injury in Patients with Diabetes Mellitus on SGLT-2 Inhibitors.
    Perlman A; Heyman SN; Stokar J; Darmon D; Muszkat M; Szalat A
    Isr Med Assoc J; 2018 Aug; 20(8):513-516. PubMed ID: 30084579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i).
    Alqudsi M; Velez JCQ; Navarrete J
    Curr Opin Cardiol; 2021 Jul; 36(4):420-428. PubMed ID: 34059610
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.